mesalamine has been researched along with End Stage Liver Disease in 1 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
End Stage Liver Disease: Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An increased risk of colorectal cancer (CRC) is present also after LT in IBD patients with primary sclerosing cholangitis (PSC)." | 2.50 | Clinical management of inflammatory bowel disease in the organ recipient. ( Indriolo, A; Ravelli, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Indriolo, A | 1 |
| Ravelli, P | 1 |
1 review available for mesalamine and End Stage Liver Disease
| Article | Year |
|---|---|
Clinical management of inflammatory bowel disease in the organ recipient.
Topics: Azathioprine; Cholangitis, Sclerosing; Colectomy; Colorectal Neoplasms; End Stage Liver Disease; Gra | 2014 |